These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25048167)

  • 21. Nab-Paclitaxel monotherapy as a treatment of patients with metastatic breast cancer in routine clinical practice.
    Aigner J; Marmé F; Smetanay K; Schuetz F; Jaeger D; Schneeweiss A
    Anticancer Res; 2013 Aug; 33(8):3407-13. PubMed ID: 23898112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
    Hirsh V
    Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain.
    Wiedenmann N; Valdecanas D; Hunter N; Hyde S; Buchholz TA; Milas L; Mason KA
    Clin Cancer Res; 2007 Mar; 13(6):1868-74. PubMed ID: 17363543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
    Lipp HP
    Med Monatsschr Pharm; 2013 Jan; 36(1):14-24. PubMed ID: 23379109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
    Montero AJ; Adams B; Diaz-Montero CM; Glück S
    Expert Rev Clin Pharmacol; 2011 May; 4(3):329-34. PubMed ID: 22114779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
    Kinoshita R; Ishima Y; Chuang VTG; Nakamura H; Fang J; Watanabe H; Shimizu T; Okuhira K; Ishida T; Maeda H; Otagiri M; Maruyama T
    Biomaterials; 2017 Sep; 140():162-169. PubMed ID: 28651144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the role of nab-paclitaxel (Abraxane) in women with aggressive metastatic breast cancer.
    Ciruelos E; Jackisch C
    Expert Rev Anticancer Ther; 2014 May; 14(5):511-21. PubMed ID: 24575935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer.
    Neesse A; Michl P; Tuveson DA; Ellenrieder V
    Z Gastroenterol; 2014 Apr; 52(4):360-6. PubMed ID: 24687799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
    Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
    Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.
    Kudlowitz D; Muggia F
    Expert Opin Drug Saf; 2014 Jun; 13(6):681-5. PubMed ID: 24749649
    [No Abstract]   [Full Text] [Related]  

  • 31. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status.
    Desai NP; Trieu V; Hwang LY; Wu R; Soon-Shiong P; Gradishar WJ
    Anticancer Drugs; 2008 Oct; 19(9):899-909. PubMed ID: 18766004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer.
    Cullis J; Siolas D; Avanzi A; Barui S; Maitra A; Bar-Sagi D
    Cancer Immunol Res; 2017 Mar; 5(3):182-190. PubMed ID: 28108630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
    Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
    Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
    Stinchcombe TE
    Nanomedicine (Lond); 2007 Aug; 2(4):415-23. PubMed ID: 17716129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albumin-bound paclitaxel in solid tumors: clinical development and future directions.
    Kundranda MN; Niu J
    Drug Des Devel Ther; 2015; 9():3767-77. PubMed ID: 26244011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update.
    Simon GR
    Clin Lung Cancer; 2014 Nov; 15(6):391-7. PubMed ID: 25246384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Chirgwin J; Chua SL
    Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.
    Schneeweiss A; Seitz J; Smetanay K; Schuetz F; Jaeger D; Bachinger A; Zorn M; Sinn HP; Marmé F
    Anticancer Res; 2014 Nov; 34(11):6609-15. PubMed ID: 25368265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
    González-Martín A; Alba E; Ciruelos E; Cortés J; Llombart A; Lluch A; Andrés R; Álvarez I; Aramendía JM; de la Peña FA; Barnadas A; Batista N; Calvo L; Galve E; García-Palomo A; García-Sáenz JÁ; de la Haba J; López R; López-Vivanco G; Martínez-Jáñez N; de Dueñas EM; Plazaola A; Rodríguez-Lescure Á; Ruiz M; Sánchez-Rovira P; Santaballa A; Seguí MÁ; Tusquets I; Zamora P; Martín M
    Curr Cancer Drug Targets; 2016; 16(5):415-28. PubMed ID: 26278712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.